EUVIMEDEUVIMED entdecken
Crossref

Congenital Myasthenic Syndrome: Long‐Term Outcomes up to 60 Years, Molecular Characterization, and Eight Novel Variants

Ayfer Arduç Akçay iD, Gulshan Yunisova iD, Şahin Avcı iD, Ayşe Nur Özdağ Acarlı iD, Hülya Kayserili iD, Piraye Oflazer iD

Clinical Genetics · 2026

DOI: 10.1111/cge.70127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Genetics, 2026. Verfasst von Ayfer Arduç Akçay und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Neurology, Department of Pediatrics, School of Medicine, Koç University, İstanbul, Türkiye. Hauptthemen laut MEDLINE: Myasthenic Syndromes, Congenital, Genetic Predisposition to Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Congenital myasthenic syndrome (CMS) refers to a rare heterogeneous group of hereditary disorders characterized by fatigue and muscle weakness due to impairment in neuromuscular transmission. A total of 40 genes have been identified in the pathogenesis of CMSs. The study assessed 22 patients (14 females and 8 males) with CMS of childhood onset with their phenotypes and genotypes. Genetic analysis revealed variations in the following eight genes: CHRNE , DOK7 , GFPT1 , COLQ , SLC25A1 , CHAT , MUSK , and MYO9A. Eight novel variations were detected involving SLC25A1 , MUSK , DOK7 , GFPT1 , and CHRNE . The median age was 14 years (range: 0.5–67 years). The median age of onset of symptoms was 8 months (range: 0–16 years). The longest time after the onset of symptoms was 62 years. The most common initial symptoms were weakness of extremities ( n = 9) and ptosis ( n = 8). Respiratory symptoms were present in 11 patients (50%), which showed progression, multiphasic disease course, and amelioration in 45.4%, 18.1%, and 36.3% of patients, respectively. Motor symptoms showed a progressive worsening in 68.1%, stationary course in 13.6%, multiphasic disease course in 13.6%, and amelioration in 4.5% of patients. Thanks to next‐generation sequencing, diagnoses of CMS have been increasing over the recent years; so has the number of novel variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenic Syndromes, CongenitalGenetic Predisposition to DiseaseHumansMaleFemaleChildAdolescentChild, PreschoolInfantAdultYoung AdultMiddle AgedAgedPhenotypeMutationMuscle ProteinsInfant, NewbornGenetic Association StudiesAge of OnsetReceptors, CholinergicReceptor Protein-Tyrosine Kinases

Stichwörter der Autor:innen

congenital myasthenic syndromegenomic diagnosismuscle weaknessvariation

Substanzen

Muscle ProteinsDOK7 protein, humanMUSK protein, humanReceptors, CholinergicReceptor Protein-Tyrosine Kinases

Autor:innen und Institutionen

  • Division of Pediatric Neurology, Department of Pediatrics, School of Medicine, Koç University, İstanbul, Türkiye.
  • Department of Neurology, Koç University Hospital, İstanbul, Türkiye.
  • Department of Medical Genetics, School of Medicine, Koç University, İstanbul, Türkiye.
  • Department of Neurology, School of Medicine, Koç University, İstanbul, Türkiye.

ORCID-Profile: Ayfer Arduç Akçay, Gulshan Yunisova, Şahin Avcı, Ayşe Nur Özdağ Acarlı, Hülya Kayserili, Piraye Oflazer

Zitieren

APA

Akçay, A. A., Yunisova, G., Avcı, Ş., Acarlı, A. N. Ö., Kayserili, H., & Oflazer, P. (2026). Congenital Myasthenic Syndrome: Long‐Term Outcomes up to 60 Years, Molecular Characterization, and Eight Novel Variants. Clinical Genetics. https://doi.org/10.1111/cge.70127

Vancouver

Akçay AA, Yunisova G, Avcı Ş, Acarlı ANÖ, Kayserili H, Oflazer P. Congenital Myasthenic Syndrome: Long‐Term Outcomes up to 60 Years, Molecular Characterization, and Eight Novel Variants. Clinical Genetics. 2026. doi:10.1111/cge.70127

BibTeX
@article{Akay2026,
  author = {Akçay, Ayfer Arduç and Yunisova, Gulshan and Avcı, Şahin and Acarlı, Ayşe Nur Özdağ and Kayserili, Hülya and Oflazer, Piraye},
  title = {Congenital Myasthenic Syndrome: Long‐Term Outcomes up to 60 Years, Molecular Characterization, and Eight Novel Variants},
  journal = {Clinical Genetics},
  year = {2026},
  doi = {10.1111/cge.70127}
}
Kostenlos starten →